HC Wainwright Predicts Stronger Earnings for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) – Research analysts at HC Wainwright boosted their Q4 2025 earnings estimates for Biomea Fusion in a research report issued to clients and investors on Tuesday, October 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.20) per share for the quarter, up from their previous estimate of ($0.23). The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s FY2026 earnings at ($1.21) EPS, FY2027 earnings at ($1.24) EPS and FY2028 earnings at ($1.44) EPS.

Biomea Fusion (NASDAQ:BMEA) last announced its earnings results on Tuesday, August 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08.

A number of other brokerages have also issued reports on BMEA. Jefferies Financial Group started coverage on shares of Biomea Fusion in a research report on Thursday, August 28th. They issued a “buy” rating and a $5.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a research report on Wednesday, October 8th. Scotiabank decreased their target price on shares of Biomea Fusion from $30.00 to $10.00 and set a “sector outperform” rating for the company in a research report on Wednesday, August 6th. D. Boral Capital reiterated a “buy” rating and issued a $16.00 target price on shares of Biomea Fusion in a research report on Friday, October 3rd. Finally, Oppenheimer restated an “outperform” rating on shares of Biomea Fusion in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Biomea Fusion Stock Down 3.6%

Shares of BMEA opened at $1.59 on Thursday. The firm has a 50-day moving average price of $1.88 and a 200 day moving average price of $1.87. The firm has a market capitalization of $94.62 million, a PE ratio of -0.52 and a beta of -0.12. Biomea Fusion has a 52-week low of $1.29 and a 52-week high of $12.85.

Hedge Funds Weigh In On Biomea Fusion

Several large investors have recently made changes to their positions in BMEA. Griffin Asset Management Inc. lifted its position in shares of Biomea Fusion by 19.5% in the third quarter. Griffin Asset Management Inc. now owns 61,300 shares of the company’s stock worth $124,000 after purchasing an additional 10,000 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Biomea Fusion in the second quarter worth approximately $26,000. CWM LLC lifted its position in shares of Biomea Fusion by 8,058.5% in the first quarter. CWM LLC now owns 16,888 shares of the company’s stock worth $36,000 after purchasing an additional 16,681 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Biomea Fusion in the first quarter worth approximately $37,000. Finally, Exchange Traded Concepts LLC lifted its position in shares of Biomea Fusion by 140.9% in the first quarter. Exchange Traded Concepts LLC now owns 50,550 shares of the company’s stock worth $108,000 after purchasing an additional 29,565 shares in the last quarter. Institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.